Canadian Journal of Gastroenterology and Hepatology / 2021 / Article / Tab 2 / Research Article
Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study Table 2 Clinical features and laboratory results of patients with primary biliary cholangitis and those with primary biliary cholangitis complicated with Sjögren’s syndrome.
Parameters PBC group (n = 328) PBC-SS group (n = 133) ALT (U/L) 56.60 (28.70–111.10) 54.20 (30.20–90.10) 0.419 AST (U/L) 70.30 (41.55–114.90) 74.20 (49.30–107.80) 0.714 TBIL (μ mol/L) 27.80 (14.90–75.30) 27.90 (18.30–64.30) 0.585 DBIL (μ mol/L) 15.00 (5.80–53.35) 13.50 (8.80–52.20) 0.512 TP (g/L) 70.60 (63.60–76.70) 70.20 (63.90–81.50) 0.313 ALB (g/L) 34.80 (29.60–38.80) 33.30 (29.70–36.80) 0.008 GGT (U/L) 168.5 (76.9–358.8) 156.3 (118–305.6) 0.284 ALP (U/L) 189.30 (114.40–340.80) (114.40∼340.80) 245.8 (162.4–454.7) 0.558 WBC count (109/L) 4.63 (3.42–6.30) 3.22 (2.58–4.22) 0.013 NE% (%) 59.06 (50.38–68.90) 58.8 (49.85–65.74) 0.682 Hb (g/L) 114.6 (98.60–128.00) 112.9 (79.8–121.8) 0.003 PLT (109/L) 129.90 (77.30–196.20) 84.40 (76.00–124.00) 0.118 PT (s) 12.30 (11.10–14.10) 12.60 (11.50–13.80) 0.128 APTT (s) 34.30 (30.83–37.75) 36.25 (34.00–37.68) 0.321 UREA (mmol/L) 4.85 (3.82–6.58) 4.82 (3.76–6.23) 0.102 CREA (mmol/L) 57.00 (50.00–67.95) 56.00 (47.00–75.00) 0.374 IgM (g/L) 2.79 (1.58–4.25) 2.62 (1.47–5.10) 0.541 IgG (g/L) 15.40 (12.50–19.00) 17.70 (11.33–22.65) 0.111 AFP (ng/mL) 3.70 (2.58–5.50) 3.70 (2.00–5.40) 0.139 TC (mmol/L) 4.29 (3.39–5.49) 4.32 (3.29–5.13) 0.391 TG (mmol/L) 1.05 (0.66–1.58) 1.02 (0.66–1.54) 0.241 HDL-C (mmol/L 1.08 (0.60–1.51) 1.02 (0.46–1.27) 0.015 LDL-C (mmol/L) 2.32 (1.69–3.04) 2.44 (1.74–2.83) 0.177 Ca2+ (mmol/L) 2.18 (2.06–2.27) 2.15 (2.08–2.25) 0.004 PHOS (mmol/L) 1.08 (0.96–1.20) 1.11 (0.95–1.19) 0.116 ANA+ 164/280 (58.6%) 76/125 (60.80%) 0.673 ACA+ 60/319 (18.81%) 25/126 (19.84%) 0.803 SS-A/Ro-52kD+ 95/287 (33.10%) 57/118 (48.31%) 0.004 AMA+ 218/312 (69.9%) 107/130 (82.3%) 0.007 AMA-M2+ 191/314 (60.80%) 101/129 (78.3%) <0.001 Fatigue 132/328 (40.24%) 44/133 (33.08%) 0.152 Pruritus 44/328 (40.24%) 12/133 (9.02%) 0.191 Cirrhosis 219/328 (66.77%) 107/133 (80.45%) 0.003 Child–Pugh score 6.00 (5.00–8.00) 6.00 (6.00–8.00) 0.263 Child–Pugh score ≥7 141/328 (42.99%) 66/133 (49.62%) 0.194 Fibrosis-4 4.79 (2.37–8.93) 5.50 (2.99–9.29) 0.303 GLOBE score 1.83 ± 1.49 1.96 ± 1.52 0.507
PBC: primary biliary cholangitis; PBC-SS: primary biliary cholangitis complicated with Sjögren’s syndrome; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; DBIL: direct bilirubin; TP: serum total protein; ALB: albumin; GGT: gamma-glutamyl transferase; ALP: alkaline phosphatase; WBC count: white blood cell count; NE%: neutrophil percentage; Hb: hemoglobin; PLT: platelet count; PT: prothrombin time; APTT: activated partial thromboplastin time; CREA: creatinine; IgM: immunoglobulin M; IgG: immunoglobulin G; AFP: alpha-1-fetoprotein; TC: Total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Ca
2+ : serum calcium; PHOS: serum phosphorus; ANA+: antinuclear antibody-positive; ACA+: anticentromere antibody-positive; SS-A/Ro-52kD: anti-SSA/Ro-52kD antibody-positive; AMA: antimitochondrial antibody-positive; AMA-M2+: antimitochondrial antibody-M2 mitochondrial subfraction-positive;
value < 0.05 was considered significant.
